Your session is about to expire
← Back to Search
Virus Therapy
Plasma Adsorption in Patients With Confirmed COVID-19
N/A
Waitlist Available
Research Sponsored by Marker Therapeutics AG
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 28
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether the D2000 Cartridge in combination with the Optia SPD Protocol can reduce the morbidity and mortality associated with SARS-CoV-2 infection in patients admitted to the ICU.
Eligible Conditions
- Breathing Failure
- Acute Respiratory Distress Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 28
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 28
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Change in Sequential Organ Failure Assessment [SOFA] scores
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Plasma Adsorption CartridgeExperimental Treatment1 Intervention
Subjects will receive one treatment per day with the D2000 Cartridge for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) for up to 4 hours (treatment cycle) for up to seven (7) days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
2020
N/A
~110
Find a Location
Who is running the clinical trial?
Terumo BCTIndustry Sponsor
21 Previous Clinical Trials
4,483 Total Patients Enrolled
Marker Therapeutics AGLead Sponsor